CA-TALKDESK
16.6.2022 11:32:11 CEST | Business Wire | Press release
Talkdesk®, Inc. , a global cloud contact center leader for customer-obsessed companies, has been chosen by Barceló Hotel Group to provide a cloud-based destination to centralize the hospitality brand’s contact center operations and improve customer experience (CX) for their clients.
Barceló Hotel Group is the hotel division of the Barceló Group, a Spanish tourism leader. Founded in 1931 by Simón Barceló, the hospitality company has continued to flourish under the leadership of three generations of the Barceló family. Barceló Hotel Group manages 60,000 guest rooms in more than 270 four- and five-star urban and leisure hotel properties across 24 countries. Their company philosophy of “forward hoteligence” inspires the brand to continue elevating the benchmark for guest experience – earning them recognition as one of the 30 largest hotel brands in the world.
Talkdesk CX Cloud™ , an end-to-end customer experience solution, helped Barceló achieve digital transformation within their contact center. The flexibility and scalability of the Talkdesk platform eased the brand through a critical pivot from geographically siloed contact centers to one centralized virtual hub for managing all customer interactions. Previously, Barceló Hotel Group contact center agents – working from various locations across the globe – were only able to focus on customer inquiries within their own geographic areas. With the Talkdesk solution, every Barceló Hotel Group agent can assist any customer at any time. Talkdesk for Salesforce™ provides agents with real-time access to key customer details, ensuring guest needs are anticipated and met. Individual agents can also access all of their communication channels, tools, and customer data on a single screen, resulting in streamlined workflows and increased efficiency. AI-powered features like Talkdesk Interaction Analytics™ and Talkdesk QM Assist™ offer valuable, real-time coaching opportunities to help agents mine every interaction for the customer insights that lead to outstanding guest experiences.
“The Barceló commitment to excellent guest service is one of the main strategic objectives of the company. It’s not just our vocation, it’s the passion that drives us forward,” said Iñigo Onieva, global digital business director, Barceló Hotel Group. “We also believe that delivering excellent guest experiences, and offering additional value during the reservation process through our contact centers, begins with giving our employees access to the best tools integrated into an omnichannel experience with Barceló.com. The Talkdesk solution presents our contact center agents with a simpler way to leverage complex data and provide a more personalized, seamless guest experience – before, during, and after staying at any one of the hotels managed by Barceló Hotel Group.”
“In hospitality and tourism, the customer journey extends beyond those moments spent enjoying five-star hotel accommodation. The brands who strive to also provide five-star guest experiences – from first inquiry to those thoughtful post-visit touchpoints – will be recognised as pioneers in the quest for guest loyalty,” said Kathie Johnson, chief marketing officer, Talkdesk. “With the Talkdesk solution, Barceló agents will have the capabilities and support needed to guide guests on that complete journey. We’re proud to partner with Barceló in achieving their customer experience goals.”
Additional Resources
- See Talkdesk recognized as a Leader in the Gartner 2020 Magic Quadrant for Contact Center as a Service
- Hear from customers about why they selected Talkdesk CX Cloud and the difference it has made in their contact centers
Social Networks
- Twitter: https://twitter.com/Talkdesk
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Talkdesk
Talkdesk® is a global cloud contact center leader for customer-obsessed companies. Our automation-first customer experience solutions optimize our customers’ most critical customer service processes. Our speed of innovation, vertical expertise, and global footprint reflect our commitment to ensuring that businesses can deliver better experiences across any industry and through any channel, resulting in higher customer satisfaction and accelerated business outcomes.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered ® trademarks of their respective holders. Use of them does not imply any affiliation or endorsement by them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005115/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
